| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2025-074 号 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 富马酸喹硫平缓释片用于治疗精神分裂症和双相情感障碍的抑郁发作。富马酸 喹硫平缓释片最早由阿斯利康（AstraZeneca）公司研发，于 2007 年 5 月在美国上 市，国内于 2013 年 10 月批准上市。目前国内获得该药品注册证书的主要有吉林天 衡药业有限公司、丽珠集团丽珠制药厂等。根据米内网数据预测，富马酸喹硫平缓 释片 2024 年国内市场销售金额约人民币 4.51 亿元。 截止目前，公司在富马酸喹硫平缓释片研发项目上已投入研发费用约人民币 1,693 万元。 三、对公司的影响 1 本次富马酸喹硫平缓释片获得国家药监局的《药品注册证书》，进一步丰富了 公司的产品线，有助于提升公司产品的市场竞争力，对公司的经营发展具有一定积 极的作用。 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性 ...

证券代码：600521 证券简称：华海药业 公告编号：临 2025-073 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于因回购股份注销调整"华海转债"转股价格 因授予限制性股票增发股份，华海转债的转股价格由 34.46 元/股调整为 33.85 元/股，具体内容详见公司于 2021 年 7 月 10 日刊登在中国证券报、上海证券报、 证券时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的《浙江华海药 业股份有限公司关于授予限制性股票增发股份调整可转债转股价格的公告》（公告 编号：临 2021-065 号）。 因向激励对象授予预留部分限制性股票，华海转债的转股价格由 33.85 元/股 调整至 33.79 元/股，具体内容详见公司于 2022 年 5 月 27 日刊登在中国证券报、 上海证券报、证券时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的 《浙江华海药业股份有限公司关于授予限制性股票增发股份调整可转债转股价格 的公告》（公告编号：临 2022-064 号）。 暨转股停复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Extended-Release Tablets, which are used to treat schizophrenia and depressive episodes of bipolar disorder [1] Summary by Relevant Categories Product Approval - The approved drug was originally developed by AstraZeneca and was launched in the United States in 2007 [1] - The approval of this drug enhances the company's product line and improves its market competitiveness [1] Market Potential - According to data from Minet, the projected domestic market sales for this drug are approximately 451 million yuan in 2024 [1] R&D Investment - The company has invested approximately 16.93 million yuan in the research and development of this project [1]

Industry Overview - Gout is a chronic disease caused by purine metabolism disorders, characterized by hyperuricemia and the deposition of urate crystals in joints and tissues, leading to various clinical symptoms [1][2] - The gout medication market in China has grown significantly, with the market size increasing from 700 million yuan in 2015 to 2.2 billion yuan in 2024 [1][10] - The prevalence of hyperuricemia in China is approximately 14%, with a patient population of around 197 million, while gout prevalence ranges from 1% to 3%, affecting approximately 15.5 to 42.29 million people [6][8] Market Dynamics - The gout medication market is primarily driven by the increasing incidence of gout and hyperuricemia due to lifestyle changes and dietary habits [10] - The market is currently experiencing a contraction due to the entry of mainstream gout medications like febuxostat into centralized procurement, but future growth is expected as patient numbers rise [10] - By 2030, the gout medication market in China is projected to exceed 10 billion yuan [10] Product Classification - Gout medications are categorized into acute anti-inflammatory analgesics and long-term urate-lowering drugs, with urate-lowering drugs accounting for about 40% of the global market [2][4] - In the domestic market, traditional drugs like febuxostat and benzbromarone hold a market share of approximately 60% [2] Competitive Landscape - The industry is characterized by intense competition, with generic drugs dominating the market while innovative drugs are rapidly being developed [14] - Major players include Kangyuan Pharmaceutical, Huahai Pharmaceutical, Yipinhong, and Hengrui Medicine, which are focusing on developing new urate-lowering agents to address the limitations of existing medications [14][15] - The introduction of centralized procurement policies has pressured generic drug prices, prompting companies to shift towards high-value innovative drugs [14] Key Companies - Hengrui Medicine is developing a new urate-lowering drug, SHR4640, which has shown significant efficacy and low toxicity, with a market application expected in 2025 [15][18] - Yipinhong is working on AR882, a new urate excretion promoter, which has received FDA support for global clinical trials [15] - Tonghua Dongbao has expanded its product pipeline in the gout treatment area, with two new drugs in clinical trials [16] Development Trends - The industry is shifting from generic to innovative drug development, with URAT1 inhibitors becoming a research focus [20] - Biologics and long-acting therapies are emerging as new growth points, with products like SEL-212 expected to enhance patient compliance and market potential [21] - Personalized treatment and combination therapies are becoming key research directions, aiming to meet unmet clinical needs [22]

Core Viewpoint - The article discusses the current state and future trends of the active pharmaceutical ingredients (API) industry in China, highlighting the competitive landscape, market dynamics, and the impact of regulatory changes on production and supply chains [4][5][6]. Industry Chain Overview - The API industry chain includes upstream basic chemicals and agriculture, midstream API production through various methods, and downstream chemical formulation production [4][5]. - The production segment of APIs requires high technical standards and is influenced by fluctuations in raw material prices and changes in downstream market demand [5]. Supply Chain Characteristics - China's API supply chain is characterized by high regional concentration and strong scale, with major production bases in East China and parts of the Midwest [7]. - The country holds a global price influence in bulk raw materials, supporting the large-scale development of the API industry, although it faces structural issues such as environmental regulations and reliance on imports for high-end intermediates [7]. Competitive Landscape - As of 2023, there are 1,661 API manufacturers in China, with significant concentrations in Jiangsu and Zhejiang provinces [9]. - Major competitors in the domestic API market include companies like New Chemical, Tianyu Co., and Prolo Pharmaceutical, which hold substantial market shares [13][14]. Market Segmentation - The API market is segmented into bulk APIs, specialty generic APIs, and patented APIs, with each segment exhibiting different growth rates and competitive dynamics [21][22]. - The bulk API market is mature with stable demand, while specialty APIs are characterized by higher technical barriers and profit margins [21]. Market Trends - The bulk API market is projected to reach approximately 300 billion RMB in 2024, with over 60% of production destined for export [23]. - The patented API market is expected to grow rapidly, with a projected market size of 30 billion RMB by 2024, driven by increasing demand from international pharmaceutical companies [24]. Production and Export Dynamics - China's API production has been increasing, with a record output of 401,000 tons in December 2023, reflecting strong downstream demand [27]. - The export value of APIs reached 42.98 billion USD in 2024, with a year-on-year growth of 5.1%, indicating a recovery from previous declines [37][39]. Future Outlook - The API industry is transitioning from a volume-driven model to a value-driven approach, focusing on high-quality and diversified development [17]. - The competitive landscape is intensifying, with price wars becoming common as companies vie for market share, leading to a 12% decrease in average export prices in 2024 [56].

Market Overview - The Shanghai Composite Index fell by 0.44% on June 10, with six industries experiencing gains, led by beauty care and banking, which rose by 1.10% and 0.48% respectively. The pharmaceutical and biotechnology sector ranked third in terms of gains [1] - The defense and military industry and the computer sector saw the largest declines, with drops of 1.97% and 1.87% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 45.141 billion yuan, with five industries seeing net inflows. The banking sector led with a net inflow of 871 million yuan, while the public utilities sector had a slight decline of 0.04% and a net inflow of 822 million yuan [1] - A total of 26 industries experienced net capital outflows, with the electronics sector leading at 7.532 billion yuan, followed by the computer sector with 7.427 billion yuan. Other sectors with significant outflows included telecommunications, defense and military, and machinery equipment [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector rose by 0.33%, despite a net capital outflow of 1.883 billion yuan. Out of 475 stocks in this sector, 196 rose, with 12 hitting the daily limit, while 265 fell, including one hitting the lower limit [2] - The stocks with the highest net inflows included Harbin Sanlian with 274 million yuan, followed by Saili Medical and Huahai Pharmaceutical with 225 million yuan and 202 million yuan respectively [2] - The sector's outflow leaderboard featured Changshan Pharmaceutical with a net outflow of 351 million yuan, followed by Hanyu Pharmaceutical and Ruizhi Pharmaceutical with outflows of 295 million yuan and 182 million yuan respectively [4]

Group 1 - The CSI A500 Index (000510) experienced a decline of 0.55% as of June 10, 2025, with mixed performance among constituent stocks [1] - Zhongke Shuguang (603019) hit the daily limit up, while Junshi Biological (688180) rose by 9.36% and Huahai Pharmaceutical (600521) increased by 6.14% [1] - The leading CSI A500 ETF (563800) had a turnover of 8.13% during the trading session, with a total transaction value of 1.444 billion yuan [1] - Over the past year, the average daily trading volume of the CSI A500 ETF leader was 2.117 billion yuan [1] - The latest scale of the CSI A500 ETF leader reached 17.789 billion yuan, making it the largest in the Shanghai market [1] - The fund's scale increased by 2.084 billion yuan in the past six months, ranking it among the top two in terms of new scale among comparable funds [1] - The number of shares for the CSI A500 ETF leader grew by 2.64 billion shares in the last six months, also placing it in the top two for new shares among comparable funds [1] Group 2 - Recent market trends show increased rotation in styles, with sectors like pharmaceuticals and artificial intelligence alternating in activity [2] - The domestic computing power industry is undergoing significant restructuring, with Haiguang Information and Zhongke Shuguang announcing a share swap merger at a ratio of 1:0.5525 [2] - Huafu Securities noted that the TMT sector's transaction volume has returned to a reasonable range, indicating a potential rebound in growth styles [2] - Huazhong Securities believes that the domestic computing power sector is shifting from "single-point breakthroughs" to collaborative development across the entire industry chain [2] - The CSI A500 ETF leader provides a balanced allocation of high-quality leading companies across various industries, serving as a tool for investing in core A-share assets [2]

Group 1 - The rapid development of emerging industries in China highlights the acceleration of economic transformation, with high-tech manufacturing value-added increasing by 10% year-on-year in April [1] - Key sectors such as aerospace equipment manufacturing and integrated circuit manufacturing saw value-added growth of 21.4% and 21.3% respectively, while new energy products like new energy vehicles and charging piles experienced production increases of 38.9% and 43.1% [1] - Breakthroughs in artificial intelligence are prompting international investment banks to reassess China's supply chain, innovation advantages, and the resilience and vitality of its manufacturing ecosystem [1] Group 2 - The A500 index, which tracks a small percentage of A-share market stocks, covers 63% of total revenue and 70% of total net profit in the market, serving as a strong tool for long-term investment in China's capital market [1] - The A50 index, which focuses on large-cap leading stocks across various industries, benefits from increased market concentration due to supply-side reforms, making these stocks more attractive during earnings disclosure periods [2] - The A-share market is seen as having investment value due to rising demand for equity assets amid a "wealth shortage" phenomenon, particularly as the peak for reallocation of deposits approaches in 2025 [2]

6月10日午后，A股主要指数加速下挫，截至13点58分，核心宽基A500ETF基金（512050）跌0.64%，持 仓股表现分化，中科曙光涨停，君实生物、华海药业、乐普医疗等医药股走强，盈峰环境、深信服、用 友网络等回调居前。资金流向看，昨日该ETF获得4532万元资金净流入。 近期市场风格轮动加剧，医药、人工智能等方向交替活跃，海外不确定性因素持续扰动，市场博弈属性 加剧，布局例如中证A500指数等均衡宽基或是更好的方式，当前有不少主动权益基金放弃了沪深300等 传统宽基指数，转向了中证A500指数等新兴指数，也证明了中证A500的优质编制方案。均衡宽基 A500ETF基金（512050）助力投资者一键布局A股核心资产。该ETF所跟踪中证A500指数，采取行业均 衡配置与龙头优选双策略，细分行业全覆盖，融合价值与成长属性，相比沪深300，超配电子、医药生 物、电力设备等新质生产力行业，具备天然的哑铃投资属性。场外联接（A类：022430；C类： 022431） 国盛证券分析认为，中证A500指数未来预期收益较高：无论从未来一年还是未来三年的时间尺度来 看，中证A500指数均具备较高预期收益。未来一年指数预期 ...

Policy Developments - The Central Committee and State Council issued an opinion to improve the adjustment mechanism for the basic medical insurance drug catalog and to establish an innovative drug catalog for commercial health insurance [2] - The opinion aims to promote the sharing of high-quality medical resources and enhance the capacity of grassroots medical institutions [2] - The commercial health insurance sector is becoming a crucial lever for the high-quality development of commercial health insurance, helping to address the payment challenges for innovative drugs [3] Medical Device Approvals - DaAn Gene obtained a medical device registration certificate for six nucleic acid test kits for respiratory pathogens, expanding its product portfolio [5] - BGI Innovation received a medical device registration certificate for a human papillomavirus genotyping test kit, classified as Class III [6] - Shanghai Pharmaceuticals received approval for the production of Formoterol Fumarate inhalation solution, which is used for the maintenance treatment of chronic obstructive pulmonary disease [7] Corporate Transactions - Pilin Bio announced the resumption of trading after China National Pharmaceutical Group acquired 21.03% of its shares, changing the controlling shareholder [8] - China General Nuclear Power Corporation plans to inject 500 million yuan into its subsidiary for proton medical research and development [9] - Zhonghui Pharmaceutical completed two rounds of financing totaling nearly 50 million yuan, which will be used for the construction of a hollow microneedle medical device production base [10] Industry Developments - Dongxing Medical's subsidiary signed two contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan [11] Regulatory Alerts - Huahai Pharmaceutical received a warning letter from the FDA regarding its production facility, which may affect future ANDA applications but will not significantly impact current performance [12]